Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...

Previously, he led market access, reimbursement and marketing efforts for CAR T products as Vice President and Head of US Cell and Gene at Celgene (now Bristol-Myers Squibb). He joined Celgene ...

Previously, he led market access, reimbursement and marketing efforts for CAR T products as Vice President and Head of US Cell and Gene at Celgene (now Bristol-Myers Squibb). He joined Celgene ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader ...

Celgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws nearer. Its latest – with Immatics – bolsters its immuno-oncology business and ...

Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic. Inrebic (fedratinib) is one of a ...